Clinical trials

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Digestive diseases, Hepatology, Medicine, Progressive familial intrahepatic cholestasis, PFIC, Alagille syndrome, Cholestasis, Liver
Friday, July 10, 2020 - 10:00pm

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards are subject to the terms and conditions of Mirums 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • The companys lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Health, FDA, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Options, Corporate finance, Financial economics, Stock market, Finance, Contract law, Exercise, Equity
Friday, July 10, 2020 - 2:00pm

The options were granted as an inducement equity award outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by the new employee.

Key Points: 
  • The options were granted as an inducement equity award outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by the new employee.
  • The options are subject to the terms and conditions of a stock option agreement covering the grant and the GlycoMimetics, Inc. Inducement Plan, which was adopted January 22, 2020 and provides for the granting of stock options to new employees.
  • The stock option award has an exercise price equal to the closing price of the Companys common stock on July 06, 2020.
  • GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist.

ITM and RadioMedix announce Drug Master File Submission for ITM’s 68Ge/68Ga Generator GeGant® for the U.S. Market

FDA, Health, Clinical trials, Radiology, Pharmaceutical, Biotechnology, Physical sciences, Chemistry, GBQ, Gallium, Electric generator
Friday, July 10, 2020 - 1:46pm

68Ga is among the most important players in this field said Dr. Ebrahim Delpassand, CEO of RadioMedix.

Key Points: 
  • 68Ga is among the most important players in this field said Dr. Ebrahim Delpassand, CEO of RadioMedix.
  • We are excited to be able to accomplish this milestone in collaboration with our long-term partner ITM, Germany.
  • RadioMedix will be the manufacturer of ITM 68Ge/68Ga Generators, for the first time in the United States.
  • GeGant is a fully shielded source of high-quality Gallium-68 available in different sizes from 1 to 4 GBq, making it the largest 68Ge/68Ga Generator on the market.

Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19

Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Organic compounds, Life sciences, Specialty drugs, Biotechnology, Gilead Sciences, Remdesivir, Gilead
Friday, July 10, 2020 - 1:30pm

Gilead has previously reported the safety and efficacy results in 53 patients hospitalized with severe COVID-19 who were receiving remdesivir treatment as part of the companys compassionate use program.

Key Points: 
  • Gilead has previously reported the safety and efficacy results in 53 patients hospitalized with severe COVID-19 who were receiving remdesivir treatment as part of the companys compassionate use program.
  • Additional analyses from the compassionate use program are being presented at the conference, including data on the use of remdesivir in pediatric patients and in pregnant and postpartum women.
  • GS-5734, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program

Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious diseases, Clinical trials, Health, Medicine, Zoonoses, Clinical research, Severe acute respiratory syndrome-related coronavirus, CoV, Mucositis, Severe acute respiratory syndrome, Antibiotic, Clinical trial, Vaccine
Friday, July 10, 2020 - 12:30pm

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients.
  • The Company expects to continue to comply with any applicable regulatory requirements with respect to discontinuing the clinical trial.
  • In addition, Oragenics has an exclusive worldwide channel collaboration with ILH Holdings, Inc. relating to the development of novel antibiotics.
  • Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein, except as required by law.

Laboratory Studies Confirm BETADINE® Antiseptic Products’ Effectiveness Against COVID-19 Virus

Medical Supplies, Retail, Health, Infectious diseases, Home Goods, Clinical trials, Health, Chemistry, Physical sciences, RTT, Zoonoses, Antiseptics, Disinfectants, Iodine, Povidone-iodine, Polyvinylpyrrolidone, PvP, Mouthwash
Thursday, July 9, 2020 - 11:37pm

Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of its BETADINE antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease.

Key Points: 
  • Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of its BETADINE antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease.
  • The products subjected to testing were: BETADINE antiseptic products, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I).
  • These results confirm our view that BETADINE antiseptic products, used appropriately and in conjunction with other preventative treatment options including PPE, can play a role in limiting the spread of infections, including COVID-19, said Raman Singh, CEO Mundipharma.
  • In-vitro and clinical studies have demonstrated that BETADINE povidone iodine kills a broad range of bacteria, viruses and fungi including antibiotic-resistant strains.

Ipsen Announces Updated Indication for Dysport® (abobotulinumtoxinA) for the Treatment of Spasticity in Children

Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Neurological disorders, Organ systems, Nervous system, RTT, Rare diseases, Botulinum toxin, Spasticity, Cerebral palsy, Amyotrophic lateral sclerosis, Upper motor neuron syndrome, Tetraplegia
Thursday, July 9, 2020 - 10:33pm

This effort illustrates our continued commitment to patients, helping to ensure children living with cerebral palsy can access the spasticity treatment thats most appropriate for them.

Key Points: 
  • This effort illustrates our continued commitment to patients, helping to ensure children living with cerebral palsy can access the spasticity treatment thats most appropriate for them.
  • Treatment with Dysport and other botulinum toxin products can result in swallowing or breathing difficulties.
  • Adults with lower limb spasticity (5%): falls, muscular weakness, and pain in extremity and with upper limb spasticity (4%): muscular weakness.
  • Pediatric patients with lower limb spasticity (10%): nasopharyngitis, cough and pyrexia and with upper limb spasticity (10%): upper respiratory tract infection and pharyngitis.

Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2020

Professional services, Health, Finance, Clinical trials, Pharmaceutical, Biotechnology, Science and technology in Israel, Teva Pharmaceutical Industries, Teva, Tel Aviv Stock Exchange, Economy of Israel, Life sciences, Industries
Thursday, July 9, 2020 - 9:00pm

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter financial results on Wednesday August 5, 2020 at 7:00 a.m.

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter financial results on Wednesday August 5, 2020 at 7:00 a.m.
  • Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m.
  • Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century.

Arcus Biosciences Announces New Employment Inducement Grants

Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Arcus
Thursday, July 9, 2020 - 9:15pm

The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.

Key Points: 
  • The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.
  • Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
  • AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer.
  • For more information about Arcus Biosciences, please visit www.arcusbio.com .

Physicians’ Education Resource® Will Host 1st Annual International Congress on the Future of Women’s Health™ Virtual Meeting

Oncology, Health, Other Health, Other Science, Clinical trials, Research, Science, Medical education, Continuing medical education
Thursday, July 9, 2020 - 7:24pm

Physicians Education Resource (PER), a leading resource for continuing medical education (CME), will host the 1st Annual International Congress on the Future of Womens Health Saturday, July 25, as a full-day live CME-certified virtual webcast.

Key Points: 
  • Physicians Education Resource (PER), a leading resource for continuing medical education (CME), will host the 1st Annual International Congress on the Future of Womens Health Saturday, July 25, as a full-day live CME-certified virtual webcast.
  • We are looking forward to hosting our inaugural CME-certified womens health congress, said Phil Talamo, president of PER.
  • Now, more than ever, it is paramount that we address these health issues for women, given the current environment.
  • The inaugural meeting will bring together more than 10 womens health care experts to cover a variety of hot topics with a focus on diagnosis and treatment.